healthprotocol.wiki

cui_2025_n1_cytokine-release-syndrome-and-rapid-tumor-response-in-a-patient-treated-with-amivantamab-and-chemotherapy

7 findings

Protocol
therapy-chemotherapy-amivantamab-pemetrexed-carboplatin-first-cycle
Outcome
biomarker-c-reactive-protein-serum-peak-milligrams-per-deciliter-measured
n
1
effect
-75
attribution
85
Protocol
therapy-chemotherapy-amivantamab-pemetrexed-carboplatin-first-cycle
Outcome
biomarker-interleukin-6-serum-peak-picograms-per-milliliter-measured
n
1
effect
-70
attribution
85
Protocol
therapy-chemotherapy-amivantamab-pemetrexed-carboplatin-first-cycle
Outcome
biomarker-lymphocyte-count-cells-per-microliter-measured
n
1
effect
-60
attribution
80
Protocol
therapy-chemotherapy-amivantamab-switch-corticosteroid-prophylaxis
Outcome
immune-cytokine-release-syndrome-absence-achieved-binary-measured
n
1
effect
80
attribution
85
Protocol
therapy-chemotherapy-amivantamab-pemetrexed-carboplatin-first-cycle
Outcome
immune-cytokine-release-syndrome-grade-measured
n
1
effect
-30
attribution
85
Protocol
therapy-chemotherapy-amivantamab-switch-corticosteroid-prophylaxis
Outcome
oncology-sustained-partial-response-recist-1-1-binary-measured
n
1
effect
40
attribution
50
Protocol
therapy-chemotherapy-amivantamab-pemetrexed-carboplatin-first-cycle
Outcome
oncology-tumor-volume-reduction-percent-ct-measured
n
1
effect
80
attribution
45